NeOnc's Nasal Drug Delivery Shows Early Promise in Brain Cancer Trial
Event summary
- NeOnc's Phase 2a study of NEO100, an intranasal formulation of perillyl alcohol, reported a 6-month progression-free survival of 48.9% in recurrent IDH1-mutant glioma patients, exceeding the 20% benchmark.
- The open-label study enrolled 24 patients and showed median overall survival of 26.09 months with no major toxicities observed.
- NeOnc aims to request a Type B meeting with the FDA to discuss a potential registrational path for NEO100.
- The study tested both the therapeutic potential of perillyl alcohol and the efficacy of intranasal drug delivery to the brain.
The big picture
NeOnc's Phase 2a results challenge the long-standing obstacle of the blood-brain barrier in brain cancer treatment. The intranasal delivery approach, if validated, could redefine drug development strategies for central nervous system diseases. The study's success hinges on demonstrating both therapeutic efficacy and the practical advantages of home administration.
What we're watching
- Regulatory Pathway
- Whether the FDA will accept the Phase 2a data as sufficient to advance NEO100 to a registrational trial.
- Delivery Mechanism Validation
- The pace at which intranasal drug delivery proves superior to conventional systemic treatments for brain cancer.
- Biomarker Identification
- How NeOnc will validate IDH1 mutation status as a predictive biomarker for NEO100's efficacy.
Related topics